Search

Methylphenidate

[A631] OROS is comprised of an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. … [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.

OTL-102

It is being investigated for the treatment of X-linked chronic granulomatous disease. … OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene.

Promazine

It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.

Capivasertib

Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually

Antithrombin III human

It is a member of the serpin superfamily.

Fluvastatin

Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. … It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

Netilmicin

The bactericidal effect of netilmiicin is not fully understood. … Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.

Azathioprine

[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. … Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic

Vanzacaftor

[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector.

Quingestanol